Home > Oncology > ESMO 2020 > Lung Cancer > PD-L1 density, a new predictive biomarker in NSCLC

PD-L1 density, a new predictive biomarker in NSCLC

ESMO 2020
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy. However, PD-L1 density could be a better biomarker, primary results of the PIONeeR trial suggest. The PIONeeR project aims to predict response and/or resistance to PD-(L)1 immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients through comprehensive agnostic multiparametric and longitudinal biomarkers assessment. Eligible are patients with advanced/metastatic NSCLC with available archived tumour tissue. Patients were treated with either nivolumab, pembrolizumab, or atezolizumab alone (second-line) or combined with chemotherapy (first-line) according to current standards. All patients were systematically re-biopsied and blood-sampled at 6 weeks of treatment. At ESMO, preliminary results, based on 100 enrolled patients, were presented [1]. Of 100 patients, 33 progressed before the 6-week milestone, 35 progressed between 6 ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on